【6.rsg385.top】

모바일릴게임사이트릴게임 손오공오션슬롯 먹튀파칭코게임다운로드

카카오야마토먹튀 ╊ 88.rsg385.top ╊ 무료슬롯머신

놀이터 릴박스 ╊ 64.rsg385.top ╊ 백경

야마토5 ╊ 42.rsg385.top ╊ 야마토창공

릴게임 꽁머니 ╊ 57.rsg385.top ╊ 황금성잭팟

바다이야기꽁머니환전 잭팟 슬롯 무료슬롯 얌얌 오션파라다이스 다운로드 일본 파칭코 손오공릴게임 무료슬롯버프 양귀비게임설명 슬롯 릴 게임 야마토게임사이트 바다이야기공략법 무료슬롯버프 온라인 슬롯 배팅법 슬롯머신 무료게임 무료충전릴게임 황금성게임공략방법 바다신2다운로드 체리마스터 릴게임 체리마스터 비법 인터넷빠찡꼬 무료야마토게임 알라딘 릴게임 10원야마토 백경게임 하는곳주소 바다이야기먹튀 바다이야기 슬롯 무료카지노게임 손오공 백경게임 다운로드 인터넷릴게임 바다이야기조작 바다이야기먹튀 야마토게임공략 법 10원야마토게임 카지노 슬롯머신 종류 골드몽먹튀 릴게임횡금성 강원랜드 슬롯머신 확률 공개 모바일게임 백경온라인 야마토2 pc버전 바다이야기꽁머니환전 온라인빠찡고 바다이야기 도박 빠징코 슬롯머신 슬롯나라 바다이야기 게임 릴게임뽀빠이 오션슬롯 주소 파칭코슬롯 황금성나비 알라딘온라인릴게임 뽀빠이놀이터 신천지릴게임장주소 체리게임주소 황금성3 최신바다이야기게임 프라그마틱 무료슬롯 바다이야기상어 야마토3게임다운로드후기 슬롯머신 알고리즘 최신 릴게임 체리마스터 비법 릴게임보물섬 모바일릴게임접속하기 무료충전릴게임 야마토게임하기 릴게임정글북 오션파라 다이스다운 인터넷오션파라다이스 바다이야기시즌7 바다이야기 먹튀 무료충전릴게임 무료슬롯 얌얌 황금성다운로드 알라딘릴게임다운로드 온라인 황금성 유니티 슬롯 머신 황금성게임장주소 체리마스터 어플 바다이야기 고래 출현 오리지날야마토연타예시 바다이야기백경 슬롯머신 이기는 방법 야마토 빠칭코 예시 황금성게임공략방법 바다 슬롯 먹튀 온라인 릴게임 정보 황금성갈가리 무료카지노게임 야마토2동영상 오션파라 다이스다운로드 바다이야기게임장 파칭코하는법 양귀비 릴게임 릴게임먹튀검증 방법 일본빠찡꼬 사설바둑이 오션슬롯 체리마스터 판매 온라인 슬롯 하는 법 빠칭코게임 온라인신천지 일본경륜 럭키세븐 오션파라 다이스 사이트 온라인 릴게임 강원랜드 슬롯머신 추천 손오공릴게임예시 신천지게임 무료충전야마토 프라그마틱 슬롯 종류 슬롯머신 무료체험 빠칭코게임다운로드 빠칭코게임 릴예시게임 바다이야기pc게임 손오공게임온라인 야마토2게임하기 강원랜드 슬롯머신 추천 슬롯머신게임 우주전함 야마토 먹튀 야마토게임2 오션파다라이스 다운로드 This article was released as Pharm Edaily Premium Content on September 30, 2025, at 7:59 AM.


[Shin-Min Joon, Edaily Reporter] On September 29 shares of IlDong Pharmaceutical, AbClon and GL PharmTech(GL Pharm) stood out in the South Korean biopharmaceutical market with notable gains. IlDong Pharmaceutical attracted strong buying interest after reporting meaningful r브랜드스탁
esults from a phase 1 clinical trial of its oral obesity and diabetes drug candidate ID110521156. The drug is expected to become a best in class treatment showing superior weight loss effects compared코스피차트
to other oral obesity medications and no serious gastrointestinal or liver related side effects.
AbClon‘s stock rebounded on heightened expectations for the development of its next generat주식계좌만드는법
ion CAR-T cell therapy. Meanwhile GL PharmTech saw its shares rise due to multiple favorable factors, including the upcoming approval of Korea’s first dry eye treatment based on Recoveflavone and a re인터넷증권투자
cent reprieve from being designated as an unfaithful disclosure company.



IlDong Pharmaceutical stock trend on Sep 29. (Image=MP Doctor)

변액연급보험


IlDong Pharmaceutical Soars on Promising Oral Obesity Drug Data

IlDong Pharmaceutical‘s stock surged 26.07% to 33,900 won, marking its second consecutive day of gains. The rally followed the release of top line data from the phase 1 clinical trial of its oral obesity and diabetes candidate ID110521156 which demonstrated significant weight loss effects.
ID110521156, a GLP-1 receptor agonist, mimics the GLP-1 hormone that regulates insulin secretion, blood glucose levels, gastrointestinal motility, and appetite suppression.
The phase 1 study conducted in a randomized double blind, placebo controlled format was designed to evaluate the drug’s safety tolerability and pharmacological profile through single ascending dose (SAD) and multiple-ascending dose (MAD) studies.
In the SAD study, the drug maintained effective plasma concentrations for more than 18 hours, with a maximum of 24 hours. The MAD study confirmed favorable pharmacokinetics with no drug accumulation and minimal dietary influence supporting once daily oral dosing.
Conducted on 36 healthy adults, the MAD trial divided participants into three cohorts (50mg, 100mg, 200mg), each receiving the drug daily for 28 days. Weight reduction was dose dependent, with average reductions of 5.5%, 6.9% and 9.9% observed in the 50mg, 100mg, and 200mg groups, respectively. The maximum weight loss in the 200mg group reached 13.8%.
Over 5% weight loss was observed in 87.5% of the 200mg cohort compared to 66.7% and 55.6% in the 100mg and 50mg cohorts while the placebo group showed no such outcome. IlDong aims to begin global phase 2 trials next year and is actively pursuing licensing deals to commercialize the drug.
“This study confirms ID110521156’s strong weight loss efficacy and favorable safety profile making it a competitive candidate in the GLP-1 class,” a company official said.
“Despite being orally administered, the drug shows excellent absorption and stable blood concentration without accumulation along with efficient manufacturing and cost advantages that support commercialization.”
AbClon Rebounds on CAR-T Therapy Expectations
AbClon’s shares climbed 13.89% to 17,880 won. The company is accelerating development of its CAR-T cell therapy candidate, Nespesel (AT101), which recently received designation as an advanced biopharmaceutical for expedited review by the Ministry of Food and Drug Safety (MFDS).
Nespesel a next generation CAR-T therapy for blood cancers uses AbClon’s proprietary humanized antibody h1218 to target the membrane proximal region of the CD19 antigen. This confers rapid binding and dissociation properties.
The fast track designation allows priority review shorter evaluation times, and exemptions from some clinical trial data requirements. Nespesel is currently in phase 2 trials and is aiming for regulatory approval by next year.
In May interim phase 2 data showed an objective response rate (ORR) of 94% and complete response rate (CRR) of 63%, outperforming existing CAR-T therapies such as Kymriah (ORR 50%, CRR 32%) and Yescarta (ORR 72%, CRR 51%).
“It’s unusual for fast track approval to be granted just two months after application” a biotech industry source commented. “Nespesel is especially promising for high risk patients unresponsive to existing CAR-T therapies raising hopes for commercialization.”
GL PharmTech Rises on Dry Eye Drug and Regulatory Relief
GL PharmTech’s stock rose 7.42% to 1,158 won. The company in partnership with Aju Pharm is preparing to submit a New Drug Application (NDA) for Korea’s first dry eye treatment based on lecithin derived compound Recoveflavone, aiming for market launch next year.
The investigational drug GLH8NDE demonstrated both safety and efficacy in phase 3 trials showing statistically significant improvement in primary and secondary endpoints compared to placebo. No significant adverse events were reported.
GLH8NDE, which originated from DongA ST and was licensed in by GL PharmTech in 2017 underwent formulation enhancements to improve ocular absorption supported by two composition patents.
The dry eye market in Korea is estimated at 500 billion won and growing. GLH8NDE’s superior efficacy and lower risk of side effects position it as a strong new treatment option.
GL PharmTech was also recently granted a reprieve from being designated an unfaithful disclosure firm following a canceled merger with its wholly owned subsidiary GL Pharma. The cancellation was due to regulatory code conflicts and the potential for added costs related to product disposal.
“We plan to revisit the merger after regulatory systems are improved” a company representative said.
신민준 (adonis@edaily.co.kr)